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Although mild traumatic brain injury (mTBI), or concussion, is not typically associated
with abnormalities on computed tomography (CT), it nevertheless causes persistent cog-
nitive dysfunction for many patients. Consequently, new prognostic methods for mTBI
are needed to identify at risk cases, especially at an early and potentially treatable stage.
Here, we quantified plasma levels of the neurodegeneration biomarker calpain-cleaved αII-
spectrin N-terminal fragment (SNTF) from 38 participants with CT-negative mTBI, orthope-
dic injury (OI), and normal uninjured controls (UCs) (age range 12–30 years), and compared
them with findings from diffusion tensor imaging (DTI) and long-term cognitive assess-
ment. SNTF levels were at least twice the lower limit of detection in 7 of 17 mTBI cases
and in 3 of 13 OI cases, but in none of the UCs. An elevation in plasma SNTF corresponded
with significant differences in fractional anisotropy and the apparent diffusion coefficient
in the corpus callosum and uncinate fasciculus measured by DTI. Furthermore, increased
plasma SNTF on the day of injury correlated significantly with cognitive impairment that
persisted for at least 3 months, both across all study participants and also among the mTBI
cases by themselves. The elevation in plasma SNTF in the subset of OI cases, accompa-
nied by corresponding white matter and cognitive abnormalities, raises the possibility of
identifying undiagnosed cases of mTBI. These data suggest that the blood level of SNTF
on the day of a CT-negative mTBI may identify a subset of patients at risk of white matter
damage and persistent disability. SNTF could have prognostic and diagnostic utilities in the
assessment and treatment of mTBI.
Keywords: surrogate marker, concussion, calpain, DTI, spectrin, diffuse axonal injury, prognostic marker, cognitive
impairment
INTRODUCTION
Mild traumatic brain injury (mTBI), alternatively referred to as
concussion, is the most common neurological injury and affects
over 1.5 million children and adults each year in the United
States alone, and hundreds of thousands of military personnel
worldwide (1, 2). mTBI is typically undetectable with computed
tomography (CT),yet can elicit long-term and clinically significant
brain dysfunction in ∼15–30% of cases (3–6). Histopathological
and biomechanical findings in experimental animal models and
human cases that have come to autopsy suggest that the main
underlying structural correlate for long-term functional impair-
ment after mTBI is diffuse axonal injury (DAI) resulting from
head rotational acceleration at the moment of injury (6–10).
Developing neuroradiological methods, such as diffusion tensor
imaging (DTI), have shown promise for the detection of white
matter structural abnormalities after mTBI, but collectively these
studies have yielded inconsistent results (11, 12). Consequently,
new approaches are urgently needed for the rapid identification
of mTBI patients who are at risk of suffering brain damage and
persistent disability. In particular, a prognostic marker for mTBI
with negative long-term functional consequences would enable
the clinical evaluation of candidate neuroprotective treatments by
identifying a set of patients most appropriate for trial enrollment.
Blood-based biomarkers for brain damage have long been eval-
uated as potential prognostic measures in mTBI, but none have
emerged thus far as a means of identifying those cases of mTBI
with evolving brain damage leading to long-term dysfunction at
an early and potentially treatable stage. For example, a number of
proteins expressed predominantly in the nervous system become
detectable in the blood during the acute post-injury period in
subsets of mTBI cases. Blood levels of the astrocyte-enriched pro-
teins S100β and glial fibrillary acidic protein (GFAP), along with
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the neuron-enriched neuron-specific enolase (NSE), ubiquitin C-
terminal hydrolase L1 (UCH-L1), and a proteolytic fragment of
tau are reportedly elevated following injuries categorized as mild
based on clinical examinations using the Glasgow Coma Scale
(13–20). However, these studies either demonstrated the lack of a
prognostic relationship between blood biomarker elevations and
brain functional outcomes (13–18) or focused predominantly on
TBI cases that also show head CT abnormalities (19, 20) and would
be classified with moderate TBI or “complicated” mTBI at most
centers. There is evidence that positive CT findings are them-
selves prognostic for poorer long-term outcome after TBI (21),
and additional prognostic utility for blood markers for “com-
plicated” mTBI remains to be established. For the much more
common instances of CT-negative mTBI, blood-based markers for
brain injury that are strong predictors of structural damage and
long-term functional outcome have yet to be discovered (22, 23).
Given the challenge of early prognosis of functionally disruptive
CT-negative mTBI, it is important to evaluate new blood-based
biomarkers for neurodegeneration, and explore whether a com-
bination of biomarkers, advanced neuroimaging, and neuropsy-
chological methods may be more effective when used together
than any single approach. Toward this end, we have discovered
and begun to characterize several new candidate neurodegenera-
tion biomarkers for acute brain damage, based on proteins that
are released from degenerating neurons (24). Two of the released
proteins are calpain-cleaved αII-spectrin proteolytic fragments
[N-terminal fragment SNTF, originally referred to as BDP3 (25);
and C-terminal fragment SBDP150, originally referred to as BDP1
(25, 26)]. These spectrin derivatives are mechanism-based mark-
ers for the calpain-associated necrotic mode of neurodegeneration
especially prevalent in the brain after TBI or cerebral ischemia
(26–29). αII-Spectrin N-terminal fragment (SNTF) increases in
human blood after severe TBI (30) but has yet to be evaluated in
mTBI. In this study, we examined the levels of SNTF in human
plasma from CT-negative mTBI, orthopedic injury (OI), or unin-
jured control (UC) participants. By combining acute evaluation
of this neurodegeneration biomarker with DTI and 3 months of
neurobehavioral analyses, we examined whether SNTF might be a
marker for mTBI and, if so, whether its blood levels relate to white
matter abnormalities and persisting functional disability.
MATERIALS AND METHODS
STUDY PARTICIPANTS
The Institutional Review Boards of the University of Pennsylva-
nia and Texas Medical Center, Houston, reviewed and approved
the study. All participants in this study provided written informed
consent (or assent if written consent was given by the minor’s
parent) and were recruited and assessed with approval from and
according to the ethical guidelines of the Institutional Review
Boards of the recruiting institutions. All procedures were con-
ducted in accord with the ethical standards of the Helsinki
Declaration of 1975, as revised in 2000 (31).
This study on neurodegeneration biomarkers examined 38 par-
ticipants with plasma collected within 24 h of injury. Of those,
17 sustained mTBI, 13 sustained an OI, and 8 were UCs. These
participants were part of a larger study comprising right-handed
participants of ages 12–30 years, who were recruited and tested
on neuropsychological and brain imaging measures at baseline
(within 96 h of injury), and at follow-up sessions at 1 month (neu-
ropsychological measures only) and 3 months. Participant recruit-
ment was from a random, unselected series of patients admitted to
emergency centers in the Texas Medical Center, Houston, includ-
ing Ben Taub General Hospital, Texas Children’s Hospital, and
Memorial Herman Hospital, or, for the UC group, from the greater
Houston metropolitan area. The smaller biomarker study sub-
group was selected randomly from the overall mTBI study, and did
not differ significantly from the larger study sample on age, socioe-
conomic status (SES), race, gender, GCS score, or Extracranial
Injury Severity Score (ISS).
The 17 participants providing plasma samples that experienced
mTBI, as defined by criteria from the Centers for Disease Con-
trol, had an injury to the head from blunt trauma, acceleration,
or deceleration forces with one or more of the following condi-
tions: (1) observed or self-reported confusion, disorientation, or
impaired consciousness, dysfunction of memory at the time of
the injury, loss of consciousness lasting <30 min; and, (2) symp-
toms such as headache, dizziness, fatigue, irritability, and poor
concentration soon after the injury. Additional inclusion criteria
were a Glasgow Coma Scale score of 13–15 upon examination at
an emergency center, no abnormal findings on head CT, duration
of loss of consciousness for no more than 30 min, post-traumatic
amnesia for<24 h, and an Abbreviated Injury Score (AIS)≤3 and
an ISS of <12 modified to exclude the head region. Comparator
participants were of two cohorts. For one, participants with OI
were recruited<96 h post-injury provided they met the following
criteria: right-handed, 12–30 years old, no loss of consciousness,
no post-traumatic amnesia, no overt intracranial injury, AIS <3
for any region of the body and an ISS≤12, and a normal brain CT
(if done). A second UC cohort consisted of eight healthy partic-
ipants who had not sustained any injury, but were similar to the
two injury groups in age, gender, and level of education.
Exclusions included non-fluency in either English or Spanish,
failure to provide adequate contact information for scheduling
follow-up assessments, blood alcohol level (200 mg/dL, previous
hospitalization for head injury, pregnancy when screened prior
to brain imaging, pre-existing neurologic disorder associated with
cerebral dysfunction and/or cognitive deficit (e.g., cerebral palsy,
mental retardation, epilepsy) or diagnosed dyslexia, pre-existing
severe psychiatric disorder (e.g., bipolar disorder, schizophrenia),
and contraindications to undergoing MRI. The OI comparison
group was included to control for risk factors (32, 33) that pre-
dispose to injury, including pre-existing behavioral problems,
learning disabilities, and family variables, along with a general
trauma context similar to those with mTBI. The uninjured group
was included to examine effects not due to injury and to compare
injured patients to the general young adult population.
NEUROBEHAVIORAL ASSESSMENTS
Participants were administered tests of cognition and assessed
for symptoms related to post-concussive injury. For compari-
son with neurodegeneration biomarker findings, we analyzed data
from three domains, speed of processing, executive memory, and
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cognitive flexibility, along with symptoms of concussion. The
analyses were conducted by investigators blinded to the plasma
biomarker data.
Rivermead Post-Concussion Symptoms Questionnaire [RPCS;
(34)]. The RPCS is a 16-item self-report of cognitive, emotional,
and somatic complaints that are commonly reported following
mTBI. Factor analyses have elicited a three-factor solution com-
prising cognitive, somatic, and emotional problems (35), although
different factor structures have been reported (36). The partici-
pants were asked to rate the severity of each symptom (currently
compared to pre-injury levels) from 0 – “not experienced at all” to
4 – “severe problem.” The primary variable was the total score.
Symbol-Digit Modalities Test [SDMT; (37)]. This is a timed
substitution task with written and oral response modalities and
is highly sensitive to processing speed deficits in the 8–78 year
age range. Using a reference key, each examinee was asked to
pair specific numbers with given geometric symbols within 90 s.
The number of correct responses in the written modality was the
variable used in this study.
KeepTrack task [KT; (38, 39)]. This updating task requires
adding and deleting items in working memory according to
semantic category, and the maintenance of semantic categorical
representations. It has been validated in the mild TBI population
(40). The variable used was the mean percent correct items per list
recalled.
DIFFUSION TENSOR IMAGING
All participants underwent MRI without sedation on a Philips
3.0 T Achieva scanner. Rigorous quality assurance testing was
performed including American College of Radiology phantom
testing: no concerns with quality assurance were noted during
the course of the study.
An axial single-shot spin-echo echo-planar imaging sequence
with 30 diffusion-encoding directions was used for DTI acqui-
sition. Other parameters included a 256 mm field of view, an
acquisition voxel size of 2 mm× 2 mm× 2 mm, repetition time
of 11,526 ms, echo time of 51 ms, sensitivity encoding (SENSE)
reduction factor of 2, two B factors (0 s/mm2 low B and
1000 s/mm2 high B), with two acquisitions to average the signal of
the two DTI scans in order to ensure better signal-to-noise ratio.
DTI acquisition consisted of 70 slices. A SENSE eight-channel head
coil was used.
IMAGE PROCESSING
The corpus callosum, right and left uncinate fasciculi, and right
and left frontal lobes were selected as structures of interest due
to their known vulnerability in DTI studies of TBI and their pre-
sumed relation to the measures of speed of cognitive processing,
memory updating, and executive function, and post-concussion
symptoms. Additionally, DTI measurement of these structures has
been shown to be reproducible both between and within raters on
quantitative tractography using previously published protocols.
In this study, DTI data were analyzed twice by a single rater to
establish intra-rater reliability using intra-class correlational coef-
ficients (ICCs). A subset of the images was analyzed by two raters
to establish inter-rater reliability. ICCs for all measurements were
above 0.95.
QUANTIFYING THE NEURODEGENERATION BIOMARKER SNTF
The sandwich immunoassay for quantifying calpain-cleaved SNTF
from human plasma is a modification of a method published
previously (30, 41) in which the enzymatic amplification and
detection steps of ELISA were replaced with next-generation elec-
trochemiluminescence detection chemistry. Briefly, 96 well plastic
microplates with an underside electrode (Meso Scale Diagnostics)
were coated overnight with the capture antibody, a monoclonal
directed at the SH3 domain in the N-terminal portion of the
αII-spectrin subunit (D8/B7 @ 1/1000; Abcam). For the anti-
gen capture step, human plasma samples diluted to 40% or SNTF
standards (25µls/well) prepared in 0.25% bovine serum albumin
in Tris-buffered saline (pH 7.4) were added in triplicate for 2 h
at 22°C. The detection antibody was a purified rabbit IgG pre-
pared in our laboratory that is reactive with the calpain-generated
neoepitope at the carboxyl-end of the stable calpain-derived α-
spectrin ∼150 kDa N-terminal fragment (SNTF; 1/5,000). The
specificity of this cleavage site-specific antibody for SNTF gen-
erated by calpain proteolysis has been well established by Western
blot, protease digest, and protease inhibitor studies (24, 27, 30,
42, 43). The reporter probe was goat anti-rabbit IgG conjugated
to ruthenium (SulfoTag, Meso Scale Diagnostics, Rockville, MD,
USA; 1/500). In the presence of read buffer containing tripropy-
lamine and application of current to the plate electrode, a chemi-
luminescent product is produced in proportion to the bound
antigen. Chemiluminescent signals were quantified by a SEC-
TOR Imager 2400 system (Meso Scale Diagnostics). Standard
curves were generated using serial dilution of a preparation of
α-spectrin partially purified from brain and digested with puri-
fied calpain I, essentially as described before (44). Briefly, the
digestion was performed for 10 min at 30°C at a 300:1 ratio by
weight of spectrin extract:calpain I in a buffer of 5 mM Tris-
HCl (pH 7.8), 0.6 M KCl, 5 mM β-mercaptoethanol, 2 mM CaCl2.
Purified bovine erythrocyte calpain I for the digest was obtained
from Sigma (St. Louis, MO, USA). Reactions were quenched
and the calpain I inactivated by addition of 5 mM EDTA fol-
lowed by freeze-thaw. One unit of SNTF is defined as the signal
derived from the SNTF standard diluted to 1 nl/ml, correspond-
ing to ∼500 pg of the spectrin-containing brain extract starting
material per ml.
Control experiments were performed to distinguish SNTF-
related signals from non-specific signals emanating from het-
erophilic substances that are present in a subset of human plasma
samples and confound attempts to measure very small amounts
of target antigen (45). These control immunoassays were con-
ducted as above, except that the detecting IgG specific for SNTF
was replaced with normal IgG purified from pre-immune serum
from the same rabbit. SNTF-specific signals were calculated as the
difference between the specific and pre-immune detecting IgG sig-
nals and converted to standardized units. The minimum detection
sensitivity was 10 units. The immunoassays were conducted and
analyzed and the results replicated by investigators blinded to all
other patient data.
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RESULTS
A SUBSET OF mTBI CASES EXHIBIT LONG-TERM IMPAIRMENT IN
COGNITIVE FUNCTION
A total of 38 randomly selected participants in an ongoing larger
study of mTBI provided plasma samples on the day of injury for
quantification of the neurodegeneration biomarker SNTF: 17 were
diagnosed with mTBI and 13 with OI, whereas 8 were UCs. The
biomarker study subgroup did not differ from the overall study
group in terms of initial injury severity, age, gender, or other fac-
tors (Table 1). Among these 38 cases, brain structural integrity was
assessed by DTI within 4 days of injury for 28 of the participants.
Brain performance was evaluated by neuropsychological testing
within 4 days of injury and at 1 and 3 months thereafter for 27–29
of the participants, depending on the test battery. The three bio-
marker study cohorts did not differ significantly from one another
in age, gender, or level of education.
In comparison with the UC group, the mTBI group demon-
strated overall cognitive performance deficits at 3 months post-
injury on the SDMT, KT test, and the cognitive component of the
RPCS, similar to reports from other studies [e.g., Ref. (15, 40, 46)].
Notably, performance deficits were also observed in the OI group
relative to the UCs (40). Neuropsychological test performance
varied widely among the mTBI participants: some performed
indistinguishably from the UC group at both early and late time
points, while other participants showed impairments at the acute
and/or 1 month time point that resolved by 3 months, and a third
set exhibited dysfunction persisting out to 3 months.
PLASMA SNTF IS ELEVATED IN A SUBSET OF mTBI CASES
We evaluated SNTF as a candidate plasma biomarker for human
mTBI. This αII-spectrin fragment is generated by the calpain fam-
ily of cysteine proteases (25, 27, 44) and accumulates in axons
damaged by stretch injury in vitro or TBI in vivo (29, 47–50). It is
released from neurons upon plasma membrane disruption (24).
Here, plasma SNTF measured on the day of injury was at least
twice the lower limit of detection of 10 units in an ultrasensitive
sandwich immunoassay in a subset of participants, 7 of 17 mTBI
cases and 3 of 13 OI cases. In contrast, plasma SNTF was below 10
units in all 8 healthy UC participants. The immunoassay signals
from the positive plasma samples were confirmed as being specific
for SNTF, and not from heterophilic substances that confound
human plasma biomarker studies (45), by control experiments
in which the SNTF-specific detecting IgG was replaced with pre-
immune IgG isolated from the same rabbit. The SNTF positive
mTBI participants suffered injuries spanning a variety of mecha-
nisms from sports, assault, motor vehicle/motorcycle crashes, falls,
and being struck by a falling object. Among the SNTF positive
participants, the plasma sampling time varied from 1 to 24 h post-
injury (median 14 h), and the absolute SNTF level ranged from 20
to 150 units. The SNTF positive and negative groups did not differ
significantly from one another in age or gender.
ELEVATED PLASMA SNTF ON THE DAY OF INJURY IS RELATED TO
WHITE MATTER DAMAGE AND LONG-TERM COGNITIVE DYSFUNCTION
To examine the relationship between plasma SNTF levels on the
day of mTBI and DAI, the 28 participants among the mTBI,
OI, and UC cohorts with usable neuroradiological data were
Table 1 | Representativeness of biomarker study subgroup relative to
participants in the ongoing mTBI study.
Overall group
mean (±SD)
(n=205)
Biomarker group
mean (±SD)
(n=38)
p-Value
Age at baseline 20.2 (±5.4) 20.5 (±5.8) 0.80
SES −0.0028 (±0.79) −0.039 (±0.72) 0.80
Race % non-black 61 60 0.87
Gender % female 33 26 0.38
GCS (mTBI)% <15 23 24 0.85
Non-cranial injury severity 0.93 (±1.17) 1.37 (±1.42) 0.13
There were no differences related to demographics or injury between the
biomarker study group and the overall study group (t-test).
Table 2 | Plasma SNTF is related to diffusion tensor imaging
differences in select white matter tracts.
Region/metric Mean (SD) all
SNTF− (n=19)
Mean (SD) all
SNTF+ (n=9)
p-Value Effect
size
Corpus callosum
FA 0.496 (0.02) 0.479 (0.01) 0.034 0.91
ADC 0.821 (0.03) 0.839 (0.02) 0.13 0.63
Uncinate fasciculus, left
FA 0.405 (0.02) 0.388 (0.02) 0.09 0.73
ADC 0.754 (0.03) 0.775 (0.03) 0.14 0.63
Uncinate fasciculus, right
FA 0.389 (0.01) 0.367 (0.02) 0.001 1.48
ADC 0.774 (0.02) 0.798 (0.03) 0.035 0.89
Frontal lobes, left
FA 0.394 (0.02) 0.383 (0.02) 0.26 0.47
ADC 0.765 (0.02) 0.782 (0.02) 0.07 0.77
Frontal lobes, right
FA 0.382 (0.03) 0.381 (0.02) 0.95 0.03
ADC 0.783 (0.02) 0.794 (0.02) 0.15 0.59
Dichotomized plasma SNTF levels on the day of injury discriminate groups on
brain white matter structural integrity indexed by diffusion tensor imaging per-
formed within 96 h. Effect size is reported as Cohen’s d, where 0.2–0.49 reflects
small, 0.5–0.79 medium, and 0.8 or higher large effect size, and p-value is from
two-tailed t-test.
dichotomized as either SNTF positive or negative, and the two
groups were evaluated comparatively for white matter structural
abnormalities by DTI. Compared with the 19 SNTF negative cases
analyzed by DTI within 4 days of injury, the 9 SNTF positive cases
(7 mTBI and 2 OI) as a group exhibited significant reductions
in FA and increases in ADC in the corpus callosum and uncinate
fasciculus (Table 2). The FA and ADC are thought to quantify
the orientation and structural integrity of white matter axons, and
their differences as a function of dichotomized plasma SNTF levels
provide evidence that plasma elevations in this neurodegeneration
biomarker after injury may be related to DAI.
Long-term behavioral studies have provided evidence that
∼15–30% of CT-negative patients with mTBI develop brain
functional disability that can persist for many months post-injury
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(3–6). To examine the prognostic relationship between plasma
SNTF levels measured on the day of mTBI and long-term brain
function, participants were evaluated within 4 days and again
at 1 and 3 months post-injury on a set of tests for cognitive
performance and assessed for post-concussion symptoms. These
included written and oral versions of the SDMT, which measures
speed of cognitive processing and is a sensitive index of cognitive
functioning independent of intelligence level (37), the KT (38, 39),
a measure of memory updating and executive function, and the
RPCS (34, 51), a self-report assessment of the severity of somatic,
emotional and cognitive symptoms after concussion. For groups
dichotomized with respect to plasma SNTF levels on the day of
injury, there were marked differences in functional measures at
both the acute and long-term time points. Plasma SNTF did not
discriminate symptomatology on the overall RPCS, but showed
an association with impairments in the cognitive and somatic
components at 3 months post-injury that did not reach statistical
significance. Most importantly, a level of plasma SNTF on the day
of injury of>10 units discriminated test performance at 3 months
on the SDMT and the KT, and the relationship with the former
cognitive deficit was significant (p= 0.039; Table 3). The signifi-
cant discrimination in the written and oral versions of the SDMT
observed across all study participants based on dichotomized
plasma SNTF (Table 3) was even stronger among the mTBI cases
by themselves (written SDMT: SNTF+= 46.8; SNTF−= 59.1;
p= 0.011; oral SDMT: SNTF+= 70.1; SNTF−= 53.3; p= 0.024).
Plasma SNTF on the day of mTBI also correlated with recov-
ery of cognitive performance. Among the 13 mTBI participants
evaluated by the oral SDMT in both the acute (1–4 days) and
long-term (3 months) post-injury time periods, test scores for the
SNTF – cases improved by 17 points (±5.7 SEM), whereas those
for the SNTF+ cases worsened by 2.6 points (±2.7). The differ-
ence in 3 months recovery of cognitive performance as a function
of dichotomized plasma SNTF levels was significant (p< 0.03). Six
of eight SNTF− cases of mTBI showed improvement in cognitive
performance over 3 months of five points or greater on the oral
SDMT, compared with none of the five SNTF+ cases (Figure 1).
Based on this preliminary post hoc assessment, plasma SNTF on
the day of mTBI showed 100% sensitivity and 75% specificity for
predicting failure to improve cognitive performance over the first
3 months after a CT-negative mTBI.
DISCUSSION
In this study, we provide evidence that the blood level of the neu-
rodegeneration biomarker SNTF identifies mTBI patients on the
day of their injury likely to have both white matter changes with
advanced neuroimaging suggestive of DAI, and also cognitive dys-
function that persists for at least 3 months. Whereas a number of
brain-enriched proteins have been evaluated before as candidate
prognostic markers for cases of mTBI with negligible CT findings,
including the astrocyte-enriched S100β and GFAP along with the
neuron-enriched NSE, cleaved tau, a C-terminal fragment of αII-
spectrin termed SBDP145, and UCH-L1, none has demonstrated
a prognostic relationship with structural signs for white matter
injury or functional signs for impaired cognition (17, 22, 23, 52).
A recent study of candidate blood biomarkers in cases of repet-
itive low-level blast did not perform head CT evaluations, and
Table 3 | Plasma SNTF on the day of a mTBI relates to impaired
cognitive performance at 3months post-injury.
Test All SNTF+ All SNTF− Effect size
Symbol-digit modalities test,
written (total correct responses)
52.00 (12.1) 63.47 (14.9) 0.88
KeepTrack task (percent correct
recalled)
88.89 (7.8) 92.72 (5.6) 0.63
RiverMead post-concussion
symptoms (total score)
9.44 (10.89) 6.37 (11.08) 0.28
Dichotomized plasma SNTF levels on the day of injury (±SD in parentheses)
are related to behavioral differences 3 months post-injury. Effect size is reported
in Cohen’s d, where 0.2–0.49 reflects a small, 0.5–0.79 a medium, and 0.8 or
higher a large effect size. The difference in cognitive performance on the written
Symbol-Digit Modalities Test across all study participants based on plasma SNTF
is significant by two-tailed t-test (p<0.04), as is the difference within the mTBI
cases by themselves (SNTF+=46.8; SNTF−=59.1; p<0.025).
FIGURE 1 | Plasma SNTF discriminates 3months changes in cognitive
performance after mTBI. The difference in SDMTO scores between the
acute (1–4 day) and chronic (3 months) post-injury periods is plotted as a
function of dichotomized plasma SNTF levels on the day of mTBI. The
difference in cognitive performance recoveries between the biomarker
negative and positive mTBI groups is significant (p<0.03, two-tailed t -test).
demonstrated relationships with cognitive performance only after
analyses were conducted post hoc on a subset of 10 subjects (53).
In contrast to the prior findings with other marker candidates,
our results raise the possibility that the blood level of SNTF and
potentially other neurodegeneration biomarkers sampled in the
acute period after CT-negative mTBI might help identify at an
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early and potentially treatable stage a subset of cases at risk of
developing white matter tract structural damage and long-term
disability.
αII-Spectrin N-terminal fragment is an especially plausible bio-
marker for DAI thought to underlie long-term brain functional
impairments after mTBI (6–9, 54). It is generated by the cal-
pain family of calcium-activated proteases (25, 27, 44), and is
an N-terminal 1176 residue fragment of the α-subunit of brain
spectrin (55), an actin-binding cytoskeletal protein that is abun-
dant in axons (56, 57). SNTF is an established histological and
biochemical marker for the necrotic mode of neurodegeneration
driven by intraneuronal calcium overload and characterized by
sustained calpain activation and the degradation of a host of
functionally important cytoskeletal, cytoplasmic, and membra-
neous calpain substrates (58–60). This calpain-derived spectrin
fragment accumulates in damaged axons after stretch-induced
injury of cultured neurons (50) or after experimental TBI in
animal models (29, 47, 49) as well as in the corpus callosum of
human TBI patients (48). SNTF is released from dying neurons
in response to a variety of neurodegenerative stimuli (24). There-
fore, the injury-induced elevation in plasma SNTF in a subset of
mTBI cases reported here is consistent with the hypothesis that
functionally impactful mTBI triggers calpain activation and spec-
trin degradation within vulnerable axons, followed by efflux of
the stable fragment SNTF into the brain parenchyma and blood-
stream in association with the axon tract damage underlying brain
functional impairment.
The relationship between dichotomized plasma SNTF on the
day of injury and structural differences in the corpus callosum
and uncinate fasciculus in the acute post-injury period (Table 2)
supports this hypothesis. The SNTF positive group exhibits signif-
icant decreases in FA and increases in the ADC in the two white
matter tracts, similar to the directional changes in measures of
white matter integrity reported in the acute post-injury period in
some but not all DTI studies of mTBI (6, 11, 12). These tracts
are known to be susceptible to developing histopathology after
TBI (8, 54). As the SNTF positive and negative groups do not
differ significantly in age, the DTI differences as a function of
this blood neurodegeneration biomarker are not simply the result
of aging-dependent changes in white matter (61). The significant
relationship between plasma SNTF and alterations in FA and ADC
in the right uncinate fasciculus detectable with DTI is noteworthy,
in light of the hypothesized key functional role for this white mat-
ter pathway connecting the limbic system to prefrontal regions
(62), and the reported hemispheric functional differences in the
tract (63).
Increased plasma SNTF post-concussion is related not only
to structural evidence for DAI, but also functional evidence for
long-term cognitive impairment. Whereas a subset of the partic-
ipants with mTBI exhibit no discernible deficits on a battery of
cognitive, somatic, or emotional tests post-injury, a second group
shows performance deficits that resolve over time, while a third
group develops impaired brain performance persisting for at least
3 months post-injury. Strikingly, the dichotomized plasma level
of SNTF measured on the day of injury is related to cognitive
dysfunction at 3 months, as evidenced by a significant deficit in
the SNTF positive group in the SDMT and trends toward impair-
ments in the KT test (Table 3) and the cognitive component of the
RPCS (data not shown). The ability of plasma SNTF elevations to
significantly differentiate long-term cognitive decline holds across
all 28 participants in the mTBI, OI, and UC groups and even more
strongly among the mTBI cases by themselves. Plasma SNTF on
the day of mTBI also discriminated subsequent change in cog-
nitive performance on the SDMT, with a positive SNTF finding
predicting failure to improve cognitive performance over 3 months
post-injury (Figure 1). In contrast to these long-term measures of
cognitive function, plasma SNTF bears only a small relationship to
the 3 months RPCS, a global assessment of cognitive, somatic, and
emotional post-concussion symptoms. Further research will be
required to define the precise relationships between plasma eleva-
tions of SNTF after mTBI and different dimensions of long-term
brain performance.
The current study relating plasma SNTF to both structural and
functional outcomes after mTBI is preliminary in nature and has
several limitations, including a small sample size. For example, this
study is insufficiently powered to address whether the absolute
level of plasma SNTF might correlate with the severity of long-
lasting behavioral dysfunction among participants functionally
impacted by mTBI. The data reported here relating plasma SNTF
to DTI changes in multiple axon tracts, coupled with evidence that
this marker accumulates in damaged axons (47–50), strongly sug-
gest but do not definitively establish that the plasma increase in
SNTF after mTBI emanates from a central axonal source. The opti-
mal plasma SNTF cutoff level for the prognosis of mTBI cannot
be determined from these data alone, nor can the optimal time for
measuring it post-injury or the precise sensitivity and specificity
of the marker for functionally impactful mTBI. Plasma SNTF is
also detectable in a small fraction (<25%) of the OI cases. In this
regard, it is noteworthy that a recent study of orthopedic injuries by
DTI and neurocognitive assessments raises the possibility that they
sometimes lead to brain structural and functional abnormalities
consistent with an undiagnosed mTBI (40). Whether the plasma
rise in SNTF identifies an undiagnosed mTBI in cases of OI will
require further study. Similarly, confirmatory prognostic studies in
larger, independent cohorts of mTBI cases will be needed to deter-
mine definitively whether blood elevation in SNTF, either alone
or perhaps in combination with other neurodegeneration bio-
markers, serves as a reliable predictor of long-term outcome after
CT-negative mTBI. Conceivably, there may be prognostic value
in coupling plasma neurodegeneration biomarker findings with
advanced neuroradiological and neuropsychological approaches
for identifying mTBI patients at risk of developing brain damage
and lasting disability, but this has yet to be established.
These unresolved issues take on increased urgency given the
vital importance of early prognosis of functionally impactful
mTBI. Despite being commonly associated with negligible head
CT findings, mTBI is prevalent among both civilian and military
populations and can lead to long-term brain dysfunction in as
many as 15–30% of cases. A validated prognostic method for mTBI
would have major utilities, including: (i) for stratifying mTBI
cases and selecting a high risk population best suited for clini-
cal trials of experimental neuroprotective treatment interventions;
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(ii) for serving as a surrogate endpoint for clinical neuroprotectant
treatment trials; (iii) for rapidly identifying mTBI cases most
likely to benefit from early initiation of rehabilitation therapies
designed to improve functional outcomes; and (iv) for identify-
ing sports and military participants at increased risk of further
brain damage and disability. The current study relating SNTF to
both radiological evidence for DAI and psychological evidence for
long-term cognitive dysfunction raises the possibility that plasma
neurodegeneration biomarkers such as SNTF may have impor-
tant applications for the clinical evaluation and medical treatment
of mTBI.
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